LBO France invests EUR5m in QuantifiCare through new Digital Health 2 venture fund


QuantifiCare, a specialist in 3D imaging solutions for clinical trials and aesthetic, has raised EUR5 million from LBO France to accelerate its expansion plans and strengthen its prominent position in skin imaging worldwide.

QuantifiCare is the first investment of Digital Health 2, LBO France’s new venture fund.
 
Founded in 2001 as a spin-off of INRIA, QuantifiCare is an imaging Contract Research Organisation (CRO) specialising in skin evaluations for clinical trials to pharmaceutical and cosmetic companies in major indications such as dermatology, aesthetics, wound healing and oncology. Building upon state-of-the-art, patented technology, QuantifiCare also offers a full range of high-quality 3D cameras and software applications which are revolutionising the way plastic surgeons, dermatologists and aesthetic specialists are visualising pre and post-surgery, making treatment recommendations and ultimately improving communication with their patients.
 
QuantifiCare’s solutions have been deployed in several thousand clinical sites across sixty countries. The investment will allow the group to reinforce its leading position with top pharmaceutical sponsors and aesthetic practitioners, and further develop its existing operations in the United States, Latin America, the Middle East and Asia.
 
Jean-Philippe Thirion, Founder & CEO of QuantifiCare, says: “We are thrilled to have LBO France, a leading investor in digital health, backing QuantifiCare and joining our board to help us execute our global strategy. We already offer the most advanced 3D solutions for medical and clinical use. The funds raised will enable us to intensify our marketing, R&D and operations internationally, accelerate our growth and strengthen our leadership position in 2D/3D skin imaging worldwide.”
 
Franck Noiret, Managing Director at LBO France, adds: “QuantifiCare is a great example of the emerging power of digital technologies to finally provide objective data to medical practitioners, allowing them to better plan and validate their interventions and communicate with patients. We are delighted to partner with QuantifiCare as the first investment of Digital Health 2. QuantifiCare is revolutionising pre and post-surgery skin visualisation for both the physician and the patient, making 3D imaging a “must have” for any aesthetic procedure. Given its established positions in clinical studies and as a provider of 3D solutions to aesthetics specialists worldwide, we are confident it will continue to grow fast and innovate to improve care standards.”

specialreports
other gfm publications
GFM corporate logo